Search

Displaying results 5561 - 5570 of 8974 in total
  1. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    The results showed potent inhibition of the target, suggesting that GC-373 holds therapeutic potential for Covid-19[A219036]. … GC-373 has been shown to inhibit the M<sup>pro</sup> target in various coronavirus strains, including feline, mink, and ferret M<sup>pro</sup> [A219041].

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    Inarigivir

    go.drugbank.com/drugs/DB15062
    Investigational

    Inarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis

  3. Drug

    CEP-1347

    go.drugbank.com/drugs/DB05403
    Investigational

    prior to and after transplantation. … CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons

  4. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants

    Synonyms: 3-hydroxy-O-phosphono-L-tyrosine
  5. Drug

    Passiflora incarnata flower

    go.drugbank.com/drugs/DB13974
    Approved

    Mixtures: Bio-strath No. 8 Gouttes
  6. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  7. Drug

    Pyrrolizidine

    go.drugbank.com/drugs/DB19159
    Investigational

    Pyrrolizidine is under investigation in clinical trial NCT05898373 (Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC).

  8. Drug

    Midecamycin

    go.drugbank.com/drugs/DB13456
    Investigational

    [A33075] Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.[L2791]

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    Trefoil Factor 2

    go.drugbank.com/drugs/DB15750
    Experimental

    They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages.

  10. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.